Chronic widespread pain in spondyloarthritis

Reumatismo. 2014;66(1):28-32 DOI 10.4081/reumatismo.2014.761

 

Journal Homepage

Journal Title: Reumatismo

ISSN: 0048-7449 (Print); 2240-2683 (Online)

Publisher: PAGEPress Publications

Society/Institution: SIR

LCC Subject Category: Medicine: Internal medicine

Country of publisher: Italy

Language of fulltext: English, Italian

Full-text formats available: PDF

 

AUTHORS

F. Atzeni (Rheumatology Unit, L. Sacco University Hospital, Milan)
L. Boccassini (Rheumatology Unit, L. Sacco University Hospital, Milan)
M. Di Franco (Rheumatology Unit, Department of Internal Medicine and Medical Specialties, La Sapienza University, Rome)
A. Alciati (Hermanas Hospitalarias, FoRiPsi, Department of Clinic Neurosciences, Villa San Benedetto Menni, Albese con Cassano (CO))
A. Marsico (Reumatology Unit, S.S. Annunziata Hospital, Taranto)
M. Cazzola (Rehabilitation Unit, Busto Arsizio Ospedale di Circolo, Presidio Ospedaliero di Saronno (VA))
G. Cassisi (Rheumatology Branch, Specialist Outpatients Department, Belluno)
P. Sarzi-Puttini (Rheumatology Unit, L. Sacco University Hospital, Milan)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 10 weeks

 

Abstract | Full Text

The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.